| Peggy Ann Barrett, LMFT | |
|
417 Bay St Apt 1, Santa Monica, CA 90405-1130 | |
| (310) 367-4149 | |
| Not Available |
| Full Name | Peggy Ann Barrett |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 417 Bay St Apt 1, Santa Monica, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063638237 | NPI | - | NPPES |
| 1063638237 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 833 (California) | Secondary |
| 106H00000X | Marriage & Family Therapist | LMFT77893 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Peggy Ann Barrett, LMFT 417 Bay St Apt 1, Santa Monica, CA 90405-1130 Ph: (310) 367-4142 | Peggy Ann Barrett, LMFT 417 Bay St Apt 1, Santa Monica, CA 90405-1130 Ph: (310) 367-4149 |
News Archive
The first American study that positions Platelet Rich Plasma Therapy (PRP) as a viable means in managing knee osteoarthritis, appeared today in the December issue of the American Journal of Physical Medicine & Rehabilitation (AJPMR). The study, authored by Dr. Steven Sampson of the Orthohealing Center in Los Angeles, details the account of 14 patients with primary and secondary knee osteoarthritis receiving three platelet-rich plasma injections in the affected knee at 4-week intervals with one year follow up.
The ROMaN Project, Inc. announces its endorsement of the Food and Drug Administration's (FDA) guidance to utilize risk-based monitoring in clinical trials. Risk-based monitoring focuses attention to the most critical data elements in a study and allocates monitoring resources to the investigator sites with problematic or unproven protocol compliance and/or data integrity.
In summer 2011, University of Colorado Cancer Center investigators Joaquín Espinosa, PhD, and Matthew Galbraith, PhD, taught a summer symposium on gene expression at Cold Spring Harbor Laboratory in Long Island, New York.
Shionogi & Co., Ltd. announced today that Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the United States.
› Verified 8 days ago